Vulcan Value Partners LLC Has $103.24 Million Position in Medpace Holdings, Inc. $MEDP

Vulcan Value Partners LLC lessened its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP) by 30.4% in the third quarter, Holdings Channel reports. The institutional investor owned 200,172 shares of the company’s stock after selling 87,287 shares during the period. Medpace accounts for approximately 1.9% of Vulcan Value Partners LLC’s holdings, making the stock its 19th largest position. Vulcan Value Partners LLC’s holdings in Medpace were worth $103,241,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in MEDP. Fifth Third Wealth Advisors LLC raised its position in Medpace by 2.6% during the 3rd quarter. Fifth Third Wealth Advisors LLC now owns 737 shares of the company’s stock worth $379,000 after purchasing an additional 19 shares during the last quarter. HighPoint Advisor Group LLC grew its position in Medpace by 2.8% in the 3rd quarter. HighPoint Advisor Group LLC now owns 810 shares of the company’s stock valued at $416,000 after purchasing an additional 22 shares during the period. Portside Wealth Group LLC increased its holdings in Medpace by 2.5% during the 2nd quarter. Portside Wealth Group LLC now owns 1,090 shares of the company’s stock worth $342,000 after purchasing an additional 27 shares in the last quarter. Whittier Trust Co. of Nevada Inc. raised its holdings in shares of Medpace by 35.1% in the third quarter. Whittier Trust Co. of Nevada Inc. now owns 104 shares of the company’s stock valued at $55,000 after purchasing an additional 27 shares during the last quarter. Finally, M&T Bank Corp increased its position in shares of Medpace by 3.4% during the second quarter. M&T Bank Corp now owns 939 shares of the company’s stock valued at $295,000 after acquiring an additional 31 shares during the last quarter. 77.98% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several analysts have commented on MEDP shares. Jefferies Financial Group raised shares of Medpace from a “hold” rating to a “buy” rating and set a $560.00 price objective on the stock in a research report on Friday, February 13th. Mizuho set a $582.00 target price on shares of Medpace in a report on Wednesday, February 11th. TD Cowen raised Medpace from a “sell” rating to a “hold” rating and cut their price target for the stock from $462.00 to $419.00 in a report on Wednesday. Weiss Ratings reiterated a “buy (b)” rating on shares of Medpace in a research report on Wednesday, January 28th. Finally, BMO Capital Markets reiterated a “market perform” rating on shares of Medpace in a research note on Wednesday, February 11th. Four investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, Medpace presently has a consensus rating of “Hold” and a consensus price target of $483.45.

Medpace Price Performance

Shares of NASDAQ:MEDP opened at $453.77 on Monday. The company has a market cap of $12.88 billion, a price-to-earnings ratio of 29.66, a PEG ratio of 2.17 and a beta of 1.42. Medpace Holdings, Inc. has a one year low of $250.05 and a one year high of $628.92. The firm has a fifty day moving average price of $556.01 and a two-hundred day moving average price of $539.44.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings data on Monday, February 9th. The company reported $4.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.18 by $0.49. Medpace had a return on equity of 118.82% and a net margin of 17.83%.The company had revenue of $708.45 million during the quarter, compared to analyst estimates of $689.53 million. During the same quarter last year, the company earned $3.67 earnings per share. The firm’s quarterly revenue was up 32.0% on a year-over-year basis. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. Equities research analysts expect that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Insider Transactions at Medpace

In other Medpace news, CEO August J. Troendle sold 668 shares of the business’s stock in a transaction that occurred on Wednesday, December 3rd. The shares were sold at an average price of $590.69, for a total value of $394,580.92. Following the completion of the transaction, the chief executive officer owned 646,184 shares of the company’s stock, valued at $381,694,426.96. The trade was a 0.10% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have sold 122,720 shares of company stock worth $74,312,523 in the last three months. Insiders own 20.30% of the company’s stock.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.